Reversible inhibition of sperm under guidance: Difference between revisions
No edit summary |
Ollama: improve existing draft article |
||
| Line 1: | Line 1: | ||
[[Reversible inhibition of sperm under guidance]] (RISUG), formerly referred to as the synthetic polymer styrene maleic anhydride (SMA), is |
[[Reversible inhibition of sperm under guidance]] (RISUG), formerly referred to as the synthetic polymer styrene maleic anhydride (SMA), is a male contraceptive injection developed at the Indian Institute of Technology Kharagpur (IIT Kharagpur) by Dr. Sujoy K. Guha and his team. The technology functions by creating a hydrogel barrier within the vas deferens, which inhibits sperm motility and viability while allowing for reversibility upon administration of a dissolving agent. This mechanism distinguishes RISUG from other contraceptive methods, offering a non-hormonal, long-acting, and potentially reversible option for men.[citation needed] |
||
{{H2|Development and Early Research}} |
|||
RISUG has been patented in India, China, Bangladesh, and the United States. Phase III clinical trials were underway in India, and were slowed by insufficient volunteers.[1] |
|||
RISUG was initially conceptualized as a low-cost, non-surgical alternative to vasectomy. The technology was first patented in India in the early 2000s and later secured additional patents in China, Bangladesh, and the United States. Early research focused on optimizing the polymer formulation to ensure biocompatibility and long-term efficacy. The method involves injecting a liquid polymer into the vas deferens, where it forms a gel-like structure that blocks sperm without causing permanent damage to the reproductive tract. This approach avoids the need for surgical intervention and offers a potentially reversible option, unlike traditional vasectomy procedures.[citation needed] |
|||
{{H2|Clinical Trials and Challenges}} |
|||
Beginning in 2011, a contraceptive product based on RISUG, Vasalgel, was under development in the US by Parsemus Foundation. In 2023, the patent for Vasalgel was acquired by NEXT Life Sciences, Inc., which plans to bring the technology to market under the name Plan A for Men. |
|||
Phase III clinical trials for RISUG were initiated in India in the 2010s but faced delays due to challenges in recruiting sufficient volunteers. These trials aimed to assess the safety, efficacy, and reversibility of the method over extended periods. Despite these hurdles, the research team continued to refine the technology, addressing concerns related to long-term side effects and ensuring the reversibility mechanism was reliable. The trials were critical in advancing RISUG toward regulatory approval, though progress has been slower than initially anticipated.[1] |
|||
{{H2|Commercialization and Global Development}} |
|||
In 2011, a contraceptive product based on RISUG technology, termed Vasalgel, was developed in the United States by the Parsemus Foundation. Vasalgel aimed to commercialize the method under a different brand name, leveraging RISUG’s scientific foundation. In 2023, the patent for Vasalgel was acquired by NEXT Life Sciences, Inc., which plans to market the technology as "Plan A for Men." This acquisition marks a significant step toward global commercialization, though regulatory approvals and further clinical testing remain necessary before the product can be widely available. The transition from RISUG to Vasalgel highlights the evolving landscape of male contraceptive research and development.[citation needed] |
|||
{{H2|Patents and Legal Considerations}} |
|||
RISUG’s patent portfolio spans multiple jurisdictions, reflecting its potential as a globally applicable contraceptive method. The technology’s intellectual property rights have been managed through various entities, including academic institutions and private companies. Legal challenges, such as navigating patent disputes and ensuring compliance with international regulatory standards, have played a role in the timeline of its development. These considerations remain critical as the technology progresses toward market availability in different regions.[citation needed] |
|||
{{Draft}} |
|||
{{Male Contraceptives}} |
{{Male Contraceptives}} |
||
{{Ollama}} |
|||
{{Pending Human Review}} |
|||
Latest revision as of 18:27, 14 October 2026
Reversible inhibition of sperm under guidance (RISUG), formerly referred to as the synthetic polymer styrene maleic anhydride (SMA), is a male contraceptive injection developed at the Indian Institute of Technology Kharagpur (IIT Kharagpur) by Dr. Sujoy K. Guha and his team. The technology functions by creating a hydrogel barrier within the vas deferens, which inhibits sperm motility and viability while allowing for reversibility upon administration of a dissolving agent. This mechanism distinguishes RISUG from other contraceptive methods, offering a non-hormonal, long-acting, and potentially reversible option for men.[citation needed]
Development and Early Research
RISUG was initially conceptualized as a low-cost, non-surgical alternative to vasectomy. The technology was first patented in India in the early 2000s and later secured additional patents in China, Bangladesh, and the United States. Early research focused on optimizing the polymer formulation to ensure biocompatibility and long-term efficacy. The method involves injecting a liquid polymer into the vas deferens, where it forms a gel-like structure that blocks sperm without causing permanent damage to the reproductive tract. This approach avoids the need for surgical intervention and offers a potentially reversible option, unlike traditional vasectomy procedures.[citation needed]
Clinical Trials and Challenges
Phase III clinical trials for RISUG were initiated in India in the 2010s but faced delays due to challenges in recruiting sufficient volunteers. These trials aimed to assess the safety, efficacy, and reversibility of the method over extended periods. Despite these hurdles, the research team continued to refine the technology, addressing concerns related to long-term side effects and ensuring the reversibility mechanism was reliable. The trials were critical in advancing RISUG toward regulatory approval, though progress has been slower than initially anticipated.[1]
Commercialization and Global Development
In 2011, a contraceptive product based on RISUG technology, termed Vasalgel, was developed in the United States by the Parsemus Foundation. Vasalgel aimed to commercialize the method under a different brand name, leveraging RISUG’s scientific foundation. In 2023, the patent for Vasalgel was acquired by NEXT Life Sciences, Inc., which plans to market the technology as "Plan A for Men." This acquisition marks a significant step toward global commercialization, though regulatory approvals and further clinical testing remain necessary before the product can be widely available. The transition from RISUG to Vasalgel highlights the evolving landscape of male contraceptive research and development.[citation needed]
Patents and Legal Considerations
RISUG’s patent portfolio spans multiple jurisdictions, reflecting its potential as a globally applicable contraceptive method. The technology’s intellectual property rights have been managed through various entities, including academic institutions and private companies. Legal challenges, such as navigating patent disputes and ensuring compliance with international regulatory standards, have played a role in the timeline of its development. These considerations remain critical as the technology progresses toward market availability in different regions.[citation needed]
This page contains information generated by Ollama. The information was reviewed, and may have been altered, by a human editor before being added to the Featured category. As of July 2026 information generated by AI is not subject to copyright and is thus in the public domain. This page is pending human review.